106 related articles for article (PubMed ID: 8983288)
1. Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines.
Zaffaroni N; Orlandi L; Gornati D; De Marco C; Vaglini M; Silvestrini R
Eur J Cancer; 1996 Sep; 32A(10):1766-73. PubMed ID: 8983288
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Li L; Liu X; Glassman AB; Keating MJ; Stros M; Plunkett W; Yang LY
Cancer Res; 1997 Apr; 57(8):1487-94. PubMed ID: 9108450
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
5. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
Orlandi L; Zaffaroni N; Gornati D; Veneroni S; Silvestrini R
Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.
Takagi K; Kawai Y; Yamauchi T; Ueda T
Biochem Pharmacol; 2004 Nov; 68(9):1757-66. PubMed ID: 15450941
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Moufarij MA; Sampath D; Keating MJ; Plunkett W
Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
[TBL] [Abstract][Full Text] [Related]
10. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.
Perez RP; Handel LM; Hamilton TC
Gynecol Oncol; 1992 Jul; 46(1):82-7. PubMed ID: 1634144
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Moufarij MA; Phillips DR; Cullinane C
Mol Pharmacol; 2003 Apr; 63(4):862-9. PubMed ID: 12644587
[TBL] [Abstract][Full Text] [Related]
13. Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
Li MJ; Yang LY
Int J Oncol; 1999 Dec; 15(6):1177-83. PubMed ID: 10568825
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
[TBL] [Abstract][Full Text] [Related]
15. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to cisplatin.
Raaphorst GP; Mao J; Yang H; Goel R; Niknafs B; Shirazi FH; Yazdi HM; Rippstein P; Ng CE
Anticancer Res; 1998; 18(4C):2945-51. PubMed ID: 9713489
[TBL] [Abstract][Full Text] [Related]
18. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas S; Bonavida B; Emmanouilides C
Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
[TBL] [Abstract][Full Text] [Related]
20. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
Chen G; Zeller WJ
Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
